Loading...
XNAS
ACHV
Market cap245mUSD
Dec 05, Last price  
4.62USD
1D
-3.35%
1Q
63.25%
Jan 2017
-91.60%
Name

Achieve Life Sciences Inc

Chart & Performance

D1W1MN
XNAS:ACHV chart
P/E
—
P/S
—
EPS
—
Div Yield, %
—
Shrs. gr., 5y
138.88%
Rev. gr., 5y
%
Revenues
0k
8,254,48322,391,85820,130,66320,131,00025,539,00013,616,0005,496,00020,095,00029,882,00027,116,00018,160,0005,062,00000000000
Net income
-40m
L+33.58%
-21,097,017-23,551,296-13,063,168-4,204,0005,476,000-12,584,000-14,673,000-21,098,000-31,849,000-26,240,000-16,801,000-20,129,000-10,583,000-12,687,000-16,141,000-14,661,000-32,902,000-41,875,000-29,815,000-39,827,000
CFO
-30m
L+21.61%
-8,359,213-19,680,553-23,335,332-12,307,00034,878,000-26,840,000-20,263,000-43,493,000-35,927,000-17,308,000-9,101,000-29,683,000-9,107,000-10,623,000-15,216,000-13,474,000-29,440,000-37,549,000-24,479,000-29,770,000

Notes

No notes on this company yet
Write a private note on this company, for your eyes only
Add note

Profile

Achieve Life Sciences, Inc., a clinical-stage pharmaceutical company, develops and commercializes of cytisinicline for smoking cessation and nicotine addiction in Canada, the United States, and the United Kingdom. The company offers cytisinicline, a plant-based alkaloid that interacts with nicotine receptors in the brain that reduce the severity of nicotine withdrawal symptoms. It has license agreements with Sopharma AD and University of Bristol. The company is based in Vancouver, Canada.
URL
http://achievelifesciences.com/
IPO date
Oct 12, 1995
Employees
20
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT